KBC Securities - Hyloris Pharmaceuticals (HYL) Hyloris FIRST LOOK: Step closer to target of 30 products with addition of HY-091

Report

KBC Securities

Jacob Mekhael

Hyloris FIRST LOOK: Step closer to target of 30 products with addition of HY-091

Hyloris has entered into a partnership with AFT Pharmaceuticals (AFT) to
co-develop HY-091 (novel mucoadhesive film, target undisclosed) for the
treatment of vulvar lichen sclerosus (VLS). This new product announcement
is the first for 2024, taking Hyloris a step closer to its target of 30 products
before 2025 (currently 18 reformulated/repurposed products, and 3
generics), and as the company continues to aim for 30 products, we expect
2024 could be a busy year with respect to new product announcements. We
reiterate our BUY rating and €19.5 TP.

19/01/2024 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

KBC Securities

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

February 19, 2026 February 19, 2026 1 EN

KBC Securities

Hyloris Valacyclovir oral suspension is delayed

Hyloris provided an update regarding the review of valacyclovir for oral suspension which had a PDUFA target action date of 12 October 2025. It appears that the FDA identified significant inspection observations at the third party manufacturing plant in Greece. The manufacturer confirmed that it is actively implementing its remediation plans. Currently, Hyloris believes that resolution of the manufacturing situation is required to obtain an FDA product approval and is working on a solution. We reiterate our € 6 TP and Hold rating.

February 19, 2026 February 19, 2026 1 EN

KBC Securities

Morning Notes : ARCAD NA, GIMB BB, HYL BB, CTPNV NA

: ARCAD NA, GIMB BB, HYL BB, CTPNV NA

January 20, 2026 January 20, 2026 1 EN

Azelis Model update

After revising our estimates post FY25 results we lower our estimates. For 2026 we lower our revenue estimates as we expect lower organic growth, lower acquisitional growth and more FX headwinds. The impact on the gross profit margin is modest while we anticipate more pressure on the EBITA margins. However, we see significant upside as the current valuation is based on compressed estimates and multiples. Our DCF valuation and multiple approach result in a fair value of € 15 per share. Therefore, we reiterate our Buy rating.

5h / 36m 5h / 36m 1 EN

Mathijs Geerts Danau ... (+4)

Mathijs Geerts Danau
Michiel Declercq
Thibault Leneeuw
Wim Hoste

Morning Notes : GLPG NA, SOLB BB, AZE BB, JDEP NA

: GLPG NA, SOLB BB, AZE BB, JDEP NA

7h / 28m 7h / 28m 1 EN

Guy Sips

Guy Sips

Amoéba Transforming into an industrial and commercial company by end FY26

Amoéba stated that in FY25, major regulatory and commercial milestones have laid the groundwork for commercialisation in FY26. We maintain our positive stance (Buy, € 1.5 TP) as after FY25 marked by intense regulatory and pre-commercial activity (both in biocontrol and cosmetics, as well as recognition from agricultural and wine-growing professionals), FY26 could be a turning point for Amoéba, marking its transformation into an industrial and commercial company. This change is based on the latest regulatory advances, as the ANSES (French Agency for Food, Environmental and Occupational Health &...

7h / 41m 7h / 41m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Hyloris FIRST LOOK: Step closer to target of 30 products with addition of HY-091

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

Hyloris Valacyclovir oral suspension is delayed

Morning Notes : ARCAD NA, GIMB BB, HYL BB, CTPNV NA

Azelis Model update

Morning Notes : GLPG NA, SOLB BB, AZE BB, JDEP NA

Amoéba Transforming into an industrial and commercial company by end FY26

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe